Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,728 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: medication management Clear all
Completed No phase listed Observational Accepts healthy volunteers

The IMPROVE Study-IMPact of a Regulated ADC System

NCT02228694
View directory record Official record
Conditions
Medication Administered in Error, Medication Compliance
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
22 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 18, 2026, 5:38 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

NCT05797831
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Navtemadlin, Navtemadlin Placebo
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Vallejo, California • Atlanta, Georgia • Savannah, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 1Phase 2 Interventional

A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries

NCT00500812
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Cethrin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
16 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Cincinnati, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 3 Interventional

Safety Study of F2695 SR in Major Depressive Disorder

NCT01034267
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
F2695 SR
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
68
States / cities
Dothan, Alabama • Scottsdale, Arizona • Beverly Hills, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 18, 2026, 5:38 AM EDT
Not listed Not applicable Interventional

mHealth Facilitated Intervention to Improve Medication Adherence Among Persons Living With HIV

NCT05046392
View directory record Official record
Conditions
HIV, Medication Adherence, Telemedicine
Interventions
Face-to-Face ART Adherence Intervention, Carium Mobile Health Platform
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 4 Interventional Results available

Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy

NCT04831736
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

NCT05608005
View directory record Official record
Conditions
Influenza, Healthy Volunteers
Interventions
Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
16
States / cities
Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional

Remote Patient Monitoring and Health Coaching vs. Usual Care for the Treatment of Hypertension

NCT05394766
View directory record Official record
Conditions
Hypertension
Interventions
Omada Hypertension Program
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).

NCT06159166
View directory record Official record
Conditions
NF1, Cutaneous Neurofibroma, Monotherapy
Interventions
Mirdametinib
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 2 Interventional

Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

NCT04093895
View directory record Official record
Conditions
Periodontitis
Interventions
PerioSept(r)
Drug
Lead sponsor
Geistlich Pharma AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

NCT05174312
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Reprieve Decongestion Management System, Diuretic
Device · Drug
Lead sponsor
Reprieve Cardiovascular, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Fairhope, Alabama • Irvine, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Daratumumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
26
States / cities
Clovis, California • Fresno, California • Fort Collins, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 4 Interventional Results available

Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation

NCT03026777
View directory record Official record
Conditions
Acute Respiratory Failure, Intubation Complication
Interventions
intravenous crystalloid fluid, 500 mL
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Birmingham, Alabama • Jefferson, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 18, 2026, 5:38 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Does Intrathecal Morphine Affect Outcomes in Spine Deformity Surgery

NCT05092828
View directory record Official record
Conditions
Low Back Pain
Interventions
Intrathecal Morphine Injection, Pain Relieving
Drug
Lead sponsor
Sonoran Spine Research and Education Foundation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional

Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)

NCT00951028
View directory record Official record
Conditions
HIV, Depression, HIV Infections
Interventions
Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD), Life-steps adherence treatment, Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NCT01211483
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
U3-1287, Erlotinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

NCT02691494
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

NCT01867294
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Dermatologic Complication
Interventions
Doxycycline, Management of Therapy Complications, Placebo, Questionnaire Administration, Spironolactone, Sunscreen, Therapeutic Hydrocortisone
Drug · Procedure · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Urbana, Illinois • Des Moines, Iowa • Wichita, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 18, 2026, 5:38 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Disrupting SRFOH to Improve Substance Use and Mental Health Outcomes for Parents in Rural Regions

NCT06560866
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Just Care for Families
Behavioral
Lead sponsor
Chestnut Health Systems
Other
Eligibility
Not listed
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications

NCT01953237
View directory record Official record
Conditions
Schizophrenia
Interventions
MedActive, Smartphone
Behavioral · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 18, 2026, 5:38 AM EDT
Terminated Phase 2 Interventional

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

NCT03795428
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Pemziviptadil (PB1046) Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

NCT05806567
View directory record Official record
Conditions
Immune System Disorder, Healthy Volunteers
Interventions
Belumosudil, UGT1A1 victim drug, P-gp victim drug, OATP1B1/BCRP victim drug
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

Secondary HIV Prevention and Adherence Among HIV-infected Drug Users

NCT01741311
View directory record Official record
Conditions
Risk Behavior, Medication Adherence, HIV
Interventions
3H+ (Holistic Health for HIV), HHRP+ (Holistic Health Recovery Program)
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 18, 2026, 5:38 AM EDT